Filing Flows › Keros Therapeutics (KROS) › Stock forecast & fair value
Keros Therapeutics (KROS) stock forecast and price target
Keros Therapeutics (KROS) trades at $9.36. 6 analysts' median price target is $19.00 (+103%), from $16.00 to $25.00.
Keros Therapeutics' latest quarter
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for KROS stock?
The median of 6 analysts' 12-month targets is $19.00, +103% from $9.36; the range is $16.00 to $25.00. The average rating is none.
Does Keros Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is KROS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.